Terms: = Ovarian cancer AND MAP2K1, MAPKK1, 5604, ENSG00000169032, Q02750, MEK1, MKK1, PRKMK1 AND Prognosis
10 results:
1. The WNK1-ERK5 route plays a pathophysiological role in ovarian cancer and limits therapeutic efficacy of trametinib.
Sánchez-Fdez A; Matilla-Almazán S; Montero JC; Del Carmen S; Abad M; García-Alonso S; Bhattacharya S; Calar K; de la Puente P; Ocaña A; Pandiella A; Esparís-Ogando A
Clin Transl Med; 2023 Apr; 13(4):e1217. PubMed ID: 37029785
[TBL] [Abstract] [Full Text] [Related]
2. Protein expression profiling identifies a prognostic model for ovarian cancer.
Xiong L; Tan J; Feng Y; Wang D; Liu X; Feng Y; Li S
BMC Womens Health; 2022 Jul; 22(1):292. PubMed ID: 35840928
[TBL] [Abstract] [Full Text] [Related]
3. Low-dose triple drug combination targeting the PI3K/AKT/mTOR pathway and the MAPK pathway is an effective approach in ovarian clear cell carcinoma.
Caumanns JJ; van Wijngaarden A; Kol A; Meersma GJ; Jalving M; Bernards R; van der Zee AGJ; Wisman GBA; de Jong S
Cancer Lett; 2019 Oct; 461():102-111. PubMed ID: 31319139
[TBL] [Abstract] [Full Text] [Related]
4. Molecular manipulation of keratin 8/18 intermediate filaments: modulators of FAS-mediated death signaling in human ovarian granulosa tumor cells.
Trisdale SK; Schwab NM; Hou X; Davis JS; Townson DH
J Ovarian Res; 2016 Feb; 9():8. PubMed ID: 26911253
[TBL] [Abstract] [Full Text] [Related]
5. Unmet needs in ovarian cancer: dividing histologic subtypes to exploit novel targets and pathways.
Galic V; Coleman RL; Herzog TJ
Curr Cancer Drug Targets; 2013 Jul; 13(6):698-707. PubMed ID: 23675882
[TBL] [Abstract] [Full Text] [Related]
6. mek1/2 inhibitor selumetinib (AZD6244) inhibits growth of ovarian clear cell carcinoma in a PEA-15-dependent manner in a mouse xenograft model.
Bartholomeusz C; Oishi T; Saso H; Akar U; Liu P; Kondo K; Kazansky A; Krishnamurthy S; Lee J; Esteva FJ; Kigawa J; Ueno NT
Mol Cancer Ther; 2012 Feb; 11(2):360-9. PubMed ID: 22144664
[TBL] [Abstract] [Full Text] [Related]
7. Blockade of fatty acid synthase induces ubiquitination and degradation of phosphoinositide-3-kinase signaling proteins in ovarian cancer.
Tomek K; Wagner R; Varga F; Singer CF; Karlic H; Grunt TW
Mol Cancer Res; 2011 Dec; 9(12):1767-79. PubMed ID: 21970855
[TBL] [Abstract] [Full Text] [Related]
8. p21-activated kinase 4 regulates ovarian cancer cell proliferation, migration, and invasion and contributes to poor prognosis in patients.
Siu MK; Chan HY; Kong DS; Wong ES; Wong OG; Ngan HY; Tam KF; Zhang H; Li Z; Chan QK; Tsao SW; Strömblad S; Cheung AN
Proc Natl Acad Sci U S A; 2010 Oct; 107(43):18622-7. PubMed ID: 20926745
[TBL] [Abstract] [Full Text] [Related]
9. Tissue array analysis of expression microarray candidates identifies markers associated with tumor grade and outcome in serous epithelial ovarian cancer.
Ouellet V; Guyot MC; Le Page C; Filali-Mouhim A; Lussier C; Tonin PN; Provencher DM; Mes-Masson AM
Int J Cancer; 2006 Aug; 119(3):599-607. PubMed ID: 16572426
[TBL] [Abstract] [Full Text] [Related]
10. Oncogenic pathways implicated in ovarian epithelial cancer.
Nicosia SV; Bai W; Cheng JQ; Coppola D; Kruk PA
Hematol Oncol Clin North Am; 2003 Aug; 17(4):927-43. PubMed ID: 12959183
[TBL] [Abstract] [Full Text] [Related]
